Dr Caroline   Atkinson
Conjoint Associate Lecturer

Dr Caroline Atkinson

  • Doctorate of philosophy, Griffith University, 2016.
  • Master of Medical research, Griffith University, 2011.
  • Bachelor of Biomedical Science, Griffith University, 2008
Medicine & Health
Sch Women's&Children's Health

Originally from Queensland, I am an early career, post-doctoral researcher at the Children's Cancer Institute. My PhD, completed at Griffith University and QIMR Berghofer, focused on delineating a role for cellular prion protein in colorectal and breast cancer chemotherapeutic resistance. After completing my PhD in 2016, I joined Mater Research Institute where I assessed the functional consequences of a variant in ATM on DNA damage response signalling in melanoma. In 2017, I moved to Sydney to take a position at Children's Cancer Institute where I am currently involved in several projects aimed at improving the outcome of patients with high-risk neuroblastoma.  

Sample Publications:

  • Kamili, A., Atkinson, C., Trahair, T., Fletcher, J. Mouse Models of High-Risk Neuroblastoma (2020) Cancer and Metastasis Reviews. Doi: 10.1007/s10555-020-9855-0
  • Atkinson, C., Kawamata, F., Liu, C., Ham, S., Gyorffy, B., Munn, AL., Wei, M.Q., Moller A., Whitehall, V., Wiegmans, AP. EGFR and Prion protein (PrP) promote signalling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer. (2018) Molecular Oncology. DOI: 10.1002/1878-0261.12411
  • Wiegmans, A.P., Saunas, J., Ham, S., Lobb, R., Kutasovic, J., Dalley A., Miranda, M., Atkinson, C., Foliak S., Ferguson, k., Niland, C., Johnstone, C., Lewis, V., Collins, S., Lakhani, S., Al-Ejeh, F., Moller, A. Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer. (2019) JCI insight. 10.1172/jci.insight.124092
  • Atkinson, C., Zhang, K., Wiegmans, A., Munn, A., Wei, MQ. Prion protein scrapie and the normal cellular prion protein. (2015) Prion. 0. doi: 10.1080/19336896.2015.1110293
Location
Lvl 1- Lowy Cancer Research Centre UNSW

Publications

  • Journal articles | 2020
    Kamili A; Atkinson C; Trahair TN; Fletcher JI, 2020, 'Mouse models of high-risk neuroblastoma', Cancer and Metastasis Reviews, http://dx.doi.org/10.1007/s10555-020-09855-0
    Journal articles | 2019
    Atkinson CJ; Kawamata F; Liu C; Ham S; Győrffy B; Munn AL; Wei MQ; Möller A; Whitehall V; Wiegmans AP, 2019, 'EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer', Molecular Oncology, vol. 13, pp. 725 - 737, http://dx.doi.org/10.1002/1878-0261.12411
    Journal articles | 2019
    Wiegmans AP; Saunus JM; Ham S; Lobb R; Kutasovic JR; Dalley AJ; Miranda M; Atkinson C; Foliaki ST; Ferguson K; Niland C; Johnstone CN; Lewis V; Collins SJ; Lakhani SR; Al-Ejeh F; Möller A, 2019, 'Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer', JCI Insight, vol. 4, http://dx.doi.org/10.1172/jci.insight.124092
    Journal articles | 2016
    Atkinson CJ; Zhang K; Munn AL; Wiegmans A; Wei MQ, 2016, 'Prion protein scrapie and the normal cellular prion protein', Prion, vol. 10, pp. 63 - 82, http://dx.doi.org/10.1080/19336896.2015.1110293
    Journal articles | 2013
    Hinton C; Antony H; Hashimi SM; Munn A; Wei MQ, 2013, 'Significance of prion and prion-like proteins in cancer development, progression and multi-drug resistance', Current Cancer Drug Targets, vol. 13, pp. 895 - 904, http://dx.doi.org/10.2174/156800961131300092
    Journal articles | 2021
    Subhash VV; Huang L; Kamili A; Wong M; Chen D; Venn NC; Atkinson C; Mayoh C; Venkat P; Tyrrell V; Marshall GM; Cowley MJ; Ekert PG; Norris MD; Haber M; Henderson MJ; Sutton R; Fletcher JI; Trahair TN, 2021, 'Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma', British Journal of Cancer, http://dx.doi.org/10.1038/s41416-021-01538-z
  • Conference Papers | 2021
    Vijayasubhash V, 2021, 'Analysis of DNA minimal residual disease markers in pediatric solid cancers using quantitative real time PCR and droplet digital PCR', in Analysis of DNA minimal residual disease markers in pediatric solid cancers using quantitative real time PCR and droplet digital PCR, presented at AACR 2021, http://dx.doi.org/10.1158/1538-7445.AM2021-639
    Conference Abstracts | 2020
    Atkinson C; Tactacan C; Kamili A; Saletta F; Gana C; Eden G; Mayoh C; Lock R; Norris M; Haber M; Gifford A; Trahair T; Fletcher J, 2020, 'Abstract A35: P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma', in Poster Presentations - Proffered Abstracts, American Association for Cancer Research, presented at Abstracts: AACR Special Conference on the Advances in Pediatric Cancer Research; September 17-20, 2019; Montreal, QC, Canada, http://dx.doi.org/10.1158/1538-7445.pedca19-a35
    Conference Abstracts | 2019
    Atkinson C; Tactacan CM; Kamili A; Saletta F; Gana C; Eden GL; Mayoh C; Lock RB; Norris MD; Haber M; Gifford AJ; Trahair TN; Fletcher JI, 2019, 'Abstract 4741: Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in Experimental and Molecular Therapeutics, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.am2019-4741
    Conference Papers | 2019
    Atkinson C; Tactacan C; Kamili A; Saletta F; Gana C; Eden G; Mayoh C; Lock R; Norris M; Haber M; Gifford A; Trahair T; Fletcher J, 2019, 'P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Montreal, CANADA, pp. 61 - 61, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, Montreal, CANADA, 17 September 2019 - 20 September 2019, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2019
    Atkinson C; Tactacan CM; Kamili A; Saletta F; Gana C; Eden GL; Mayoh C; Lock RB; Norris MD; Haber M; Gifford AJ; Trahair TN; Fletcher JI, 2019, 'Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.SABCS18-4741
    Journal articles | 2021
    Subhash VV; Huang L; Kamili A; Wong M; Chen D; Venn NC; Atkinson C; Mayoh C; Venkat P; Tyrrell V; Marshall GM; Cowley MJ; Ekert PG; Norris MD; Haber M; Henderson MJ; Sutton R; Fletcher JI; Trahair TN, 2021, 'Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma', British Journal of Cancer, http://dx.doi.org/10.1038/s41416-021-01538-z
    Journal articles | 2020
    Kamili A; Atkinson C; Trahair TN; Fletcher JI, 2020, 'Mouse models of high-risk neuroblastoma', Cancer and Metastasis Reviews, http://dx.doi.org/10.1007/s10555-020-09855-0
    Journal articles | 2019
    Atkinson CJ; Kawamata F; Liu C; Ham S; Győrffy B; Munn AL; Wei MQ; Möller A; Whitehall V; Wiegmans AP, 2019, 'EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer', Molecular Oncology, vol. 13, pp. 725 - 737, http://dx.doi.org/10.1002/1878-0261.12411
    Journal articles | 2019
    Wiegmans AP; Saunus JM; Ham S; Lobb R; Kutasovic JR; Dalley AJ; Miranda M; Atkinson C; Foliaki ST; Ferguson K; Niland C; Johnstone CN; Lewis V; Collins SJ; Lakhani SR; Al-Ejeh F; Möller A, 2019, 'Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer', JCI Insight, vol. 4, http://dx.doi.org/10.1172/jci.insight.124092
    Journal articles | 2016
    Atkinson CJ; Zhang K; Munn AL; Wiegmans A; Wei MQ, 2016, 'Prion protein scrapie and the normal cellular prion protein', Prion, vol. 10, pp. 63 - 82, http://dx.doi.org/10.1080/19336896.2015.1110293
    Journal articles | 2013
    Hinton C; Antony H; Hashimi SM; Munn A; Wei MQ, 2013, 'Significance of prion and prion-like proteins in cancer development, progression and multi-drug resistance', Current Cancer Drug Targets, vol. 13, pp. 895 - 904, http://dx.doi.org/10.2174/156800961131300092

Awards

Grants

CIB - NHMRC New Ideas Grant “Improving induction therapy for high-risk neuroblastoma through bypass or inhibition of P-glycoprotein”, 2020-2021 (CIA Dr Jamie Fletcher, CIC Dr Alvin Kamili). 

Media

Neuroblastoma is the most common extracranial solid malignancy in children, comprising 8-10% of all childhood cancers and 15% of cancer related deaths. High-risk (aggressive) neuroblastoma patients account for 40% of those diagnosed and have only a 50% event-free survival rate. Currently, I am involved in several projects, with the aim of improving the survival of children with high-risk neuroblastoma. This includes defining the functional consequences of a recurrent MYCN mutation Pro44Leu, hypothesised to be a gain of function mutation, equivalent to MYCN amplification. I am also delineating the role of P-glycoprotein, a multi-drug transporter, in the resistance of high-risk neuroblastoma to standard of care chemotherapies. To continue this research, I (CIB) alongside Dr Jamie Fletcher (CIA) and Dr Alvin Kamili (CIC), were recently awarded the NHMRC Ideas Grant beginning 2020. This grant, entitled “Improving induction therapy for high-risk neuroblastoma through bypass or inhibition of P-glycoprotein”, will allow us to determine the feasibility and efficacy of combining P-gp inhibitors with induction therapies.